Unity Biotechnology, Inc. (UBX) DCF Valuation

Unity Biotechnology ، Inc. (UBX) DCF تقييم

US | Healthcare | Biotechnology | NASDAQ
Unity Biotechnology, Inc. (UBX) DCF Valuation

Fully Editable: Tailor To Your Needs In Excel Or Sheets

Professional Design: Trusted, Industry-Standard Templates

Investor-Approved Valuation Models

MAC/PC Compatible, Fully Unlocked

No Expertise Is Needed; Easy To Follow

Unity Biotechnology, Inc. (UBX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

اكتشف القيمة الحقيقية لشركة Unity Biotechnology، Inc. (UBX) مع حاسبة DCF المتقدمة! ضبط الافتراضات الرئيسية، واستكشاف السيناريوهات المختلفة، وتقييم كيفية تأثير التغييرات على Unity Biotechnology، Inc. تقييم (UBX) - كل ذلك ضمن نموذج Excel واحد مناسب.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue .0 4.8 .2 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 -95.07 -100 0 -48.77 -48.77 -48.77 -48.77 -48.77
EBITDA -89.1 -54.7 -38.7 -37.3 -31.2 .0 .0 .0 .0 .0
EBITDA, % 100 -1142.73 -16411.44 100 100 20 20 20 20 20
Depreciation 3.4 2.9 2.2 1.2 .0 .0 .0 .0 .0 .0
Depreciation, % 100 60.2 923.73 100 100 92.04 92.04 92.04 92.04 92.04
EBIT -92.6 -57.5 -40.9 -38.5 -31.2 .0 .0 .0 .0 .0
EBIT, % 100 -1202.93 -17335.17 100 100 20 20 20 20 20
Total Cash 97.7 88.1 94.8 43.2 23.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .2 1.6 .0
Account Receivables, % 100 0 99.58 100 100
Inventories .0 .0 -.2 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 0 -99.58 100 100 40.08 40.08 40.08 40.08 40.08
Accounts Payable 2.6 2.0 1.8 1.4 1.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 41.49 758.47 100 100 88.3 88.3 88.3 88.3 88.3
Capital Expenditure -.6 -.2 -.1 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 -4.08 -40.68 100 100 -8.95 -8.95 -8.95 -8.95 -8.95
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -90.6 -56.9 -39.4 -38.5 -31.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -85.2 -54.8 -37.5 -39.3 -30.0 -1.0 .0 .0 .0 .0
WACC, % 6.92 6.95 6.89 6.97 6.97 6.94 6.94 6.94 6.94 6.94
PV UFCF
SUM PV UFCF -.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt 12
Equity Value -13
Diluted Shares Outstanding, MM 17
Equity Value Per Share -0.78

What You Will Get

  • Real Unity Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Unity Biotechnology, Inc. (UBX).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
  • Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Unity’s fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to Unity Biotechnology, Inc. (UBX).
  • Time-Saving and Accurate: Avoid the hassle of building models from scratch while ensuring precision and flexibility.

Key Features

  • Comprehensive Data: Unity Biotechnology's historical financial records and pre-filled projections.
  • Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Results: Observe Unity's intrinsic value recalculating instantly.
  • Intuitive Visual Outputs: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.

How It Works

  • 1. Open the Template: Download and access the Excel file featuring Unity Biotechnology, Inc.'s (UBX) preloaded data.
  • 2. Edit Assumptions: Modify essential inputs such as growth rates, WACC, and capital investments.
  • 3. View Results Instantly: The DCF model automatically computes intrinsic value and NPV.
  • 4. Test Scenarios: Evaluate various forecasts to explore different valuation results.
  • 5. Use with Confidence: Deliver professional valuation insights to enhance your decision-making.

Why Choose This Calculator for Unity Biotechnology, Inc. (UBX)?

  • Accuracy: Utilizes real Unity Biotechnology financials for precise data.
  • Flexibility: Allows users to easily test and modify inputs as needed.
  • Time-Saving: Eliminate the complexities of constructing a DCF model from the ground up.
  • Professional-Grade: Crafted with the precision and usability expected by CFOs.
  • User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling expertise.

Who Should Use This Product?

  • Investors: Accurately estimate Unity Biotechnology’s fair value before making investment decisions.
  • CFOs: Leverage a professional-grade DCF model for financial reporting and analysis related to (UBX).
  • Consultants: Quickly adapt the template for valuation reports tailored to clients interested in (UBX).
  • Entrepreneurs: Gain insights into financial modeling techniques utilized by leading biotech firms.
  • Educators: Use it as a teaching tool to illustrate valuation methodologies specific to the biotechnology sector.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Unity Biotechnology, Inc. historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Unity Biotechnology, Inc. (UBX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.